These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29312309)

  • 1. Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.
    Didwania N; Shadab M; Sabur A; Ali N
    Front Immunol; 2017; 8():1779. PubMed ID: 29312309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
    Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
    Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status and perspectives of the immunotherapy of leishmaniasis.
    El-On J
    Isr Med Assoc J; 2009 Oct; 11(10):623-8. PubMed ID: 20077951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-an experimental study.
    Joshi J; Malla N; Kaur S
    Parasitol Int; 2014 Aug; 63(4):612-20. PubMed ID: 24747611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An appraisal of the scientific current situation and new perspectives in the treatment of cutaneous leishmaniasis.
    Briones Nieva CA; Cid AG; Romero AI; García-Bustos MF; Villegas M; Bermúdez JM
    Acta Trop; 2021 Sep; 221():105988. PubMed ID: 34058160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous Leishmaniasis: Update on Vaccine Development.
    Whyte DC; Zufferey R
    Hum Parasit Dis (Auckl); 2017; 9():. PubMed ID: 29708235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy and immunochemotherapy in combating visceral leishmaniasis.
    Yadagiri G; Singh A; Arora K; Mudavath SL
    Front Med (Lausanne); 2023; 10():1096458. PubMed ID: 37265481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Approaches and problems in vaccine development against leishmaniasis].
    Allahverdiyev A; Bağirova M; Cakir Koç R; Oztel ON; Elçıçek S; Ateş SC; Karaca TD
    Turkiye Parazitol Derg; 2010; 34(2):122-30. PubMed ID: 20597059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunity to visceral leishmaniasis: implications for immunotherapy.
    Khadem F; Uzonna JE
    Future Microbiol; 2014; 9(7):901-15. PubMed ID: 25156379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine candidates for leishmaniasis: a review.
    Nagill R; Kaur S
    Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature.
    Okwor I; Uzonna JE
    Immunotherapy; 2009 Sep; 1(5):765-76. PubMed ID: 20636022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Development of New Treatment for Leishmaniasis.
    de Menezes JP; Guedes CE; Petersen AL; Fraga DB; Veras PS
    Biomed Res Int; 2015; 2015():815023. PubMed ID: 26078965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmania vaccines: progress and problems.
    Kedzierski L; Zhu Y; Handman E
    Parasitology; 2006; 133 Suppl():S87-112. PubMed ID: 17274851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis.
    Duarte MC; Lage DP; Martins VT; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Goulart LR; Soto M; Tavares CA; Coelho EA
    Rev Soc Bras Med Trop; 2016; 49(4):398-407. PubMed ID: 27598624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent updates and perspectives on leishmaniasis.
    Savoia D
    J Infect Dev Ctries; 2015 Jul; 9(6):588-96. PubMed ID: 26142667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for the design of orally bioavailable antileishmanial treatments.
    Pham TT; Loiseau PM; Barratt G
    Int J Pharm; 2013 Sep; 454(1):539-52. PubMed ID: 23871737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current leishmaniasis drug discovery.
    Pinheiro AC; de Souza MVN
    RSC Med Chem; 2022 Sep; 13(9):1029-1043. PubMed ID: 36324493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the protective efficacy of second-generation vaccine along with standard antileishmanial drug in Leishmania donovani infected BALB/c mice.
    Joshi J; Kaur S
    Parasitology; 2014 Apr; 141(4):554-62. PubMed ID: 24618257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically modified live attenuated parasites as vaccines for leishmaniasis.
    Selvapandiyan A; Duncan R; Debrabant A; Lee N; Sreenivas G; Salotra P; Nakhasi HL
    Indian J Med Res; 2006 Mar; 123(3):455-66. PubMed ID: 16778323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.